Androgens and Acne: Perspectives on Clascoterone, the First Topical Androgen Receptor Antagonist

    April 2021 in “ Expert opinion on pharmacotherapy ”
    Leon Kircik
    Studysummary This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on tandfonline.com →
    Discuss this study in the Community →

    Research cited in this study 4

    1. The Use of Hormonal Antiandrogen Therapy in Female Patients with Acne: A 10-Year Retrospective Study American Journal of Clinical Dermatology · 2018
    2. A Review of Hormone-Based Therapies to Treat Adult Acne Vulgaris in Women International Journal of Women's Dermatology · 2017
    3. Hormonal Therapies for Acne Clinics in Dermatology · 2016
    4. Effect of Dihydrotestosterone on the Upregulation of Inflammatory Cytokines in Cultured Sebocytes Archives of Dermatological Research · 2009